FrancophonIA/ELRC3.0 huggingface dataset:
English: This is reflected in available treatment guidelines from learned societies.
Slovenian: To se odraža v dostopnih smernicah za zdravljenje, ki so jih izdala znanstvena združenja.
English: Crestor is contraindicated:
Slovenian: Crestor je kontraindiciran:
English: Crestor may be given at any time of day, with or without food.
Slovenian: Bolniki lahko Crestor zaužijejo kadar koli, bodisi s hrano bodisi brez nje.
English: {Name and address}
Slovenian: {Ime in naslov}
English: The contribution of environmental and genetic factors to these observed differences has not been determined.
Slovenian: Vpliva okolja in genetskih dejavnikov na te razlike niso ugotovili.
English: Rosuvastatin is excreted in the milk of rats.
Slovenian: Rosuvastatin se pri podganah izloča v mleko.
English: regardless of race, sex, or age and in special populations such as diabetics, or patients with familial hypercholesterolaemia.
Slovenian: ne glede na raso, spol ali starost in pri posebnih populacijah, na primer sladkornih bolnikih ali pri bolnikih z družinsko hiperholesterolemijo.
English: These patients should also start with the 5 mg dose.
Slovenian: Tudi ti bolniki morajo začeti zdravljenje s 5 mg odmerki.
English: Updated clinical trials information and post-marketing data do not provide grounds to change this assessment or to recommend specific amendments to the prescribing information for this dose level.
Slovenian: Posodobljeni podatki iz kliničnih preskušanj in postmarketinški podatki, ne nudijo zadostne podlage za spremembo te ocene ali za priporočilo za specifična dopolnila podatkov o predpisovanju za to raven odmerjanja.
English: Approximately 5% is excreted unchanged in urine.
Slovenian: Približno 5 % se ga s sečem izloči v nespremenjeni obliki.
English: ANNEX I LIST OF THE NAMES, PHARMACEUTICAL FORM, STRENGTH OF THE MEDICINAL PRODUCT, ROUTE OF ADMINISTRATION, APPLICANTS/MARKETING AUTHORISATION HOLDERS IN THE MEMBER STATES
Slovenian: DODATEK I SEZNAM IMEN, FARMACEVTSKIH OBLIK, JAKOSTI ZDRAVILA, NAČINOV UPORABE ZDRAVILA, VLAGATELJEV/IMETNIKOV DOVOLJENJA ZA PROMET Z ZDRAVILOM V DRŽAVAH ČLANICAH
English: All doses showed a beneficial effect on lipid parameters and treatment to target goals.
Slovenian: Vsi odmerki so ugodno vplivali na lipidne parametre in doseganje ciljnih vrednosti.
English: A therapeutic effect is obtained within 1 week following treatment initiation and 90% of maximum response is achieved in 2 weeks.
Slovenian: Terapevtski učinek se pojavi prvi teden zdravljenja, 90 % največjega učinka pa po dveh tednih.
English: (see Section 4.3 Contraindications).
Slovenian: (glejte poglavje 4.3 Kontraindikacije).
English: Special warnings and special precautions for use).
Slovenian: Posebna opozorila in previdnostni ukrepi).
English: No other dose adjustment is necessary in relation to age.
Slovenian: Drugega prilagajanja odmerka v zvezi s starostjo ni potrebno.
English: - concomitant use of fibrates.
Slovenian: - sočasna uporaba fibratov.
English: Safety and efficacy have not been established in children.
Slovenian: Varnost in učinkovitost uporabe zdravila pri otrocih nista dokazani.
English: Available data do not allow conclusion on a general threshold level beyond which further reduction of LDL-C is futile.
Slovenian: Na podlagi dostopnih podatkov ne moremo določiti splošnega praga, nad katerim je dodatno zniževanje LDL-C brez pomena.
English: There are no changes in pharmacokinetic parameters following multiple daily doses.
Slovenian: Farmakokinetični parametri se po več dnevnih odmerkih ne spremenijo.
English: Postfach 153, A-1037 Vienna
Slovenian: Postfach 153, A-1037 Vienna Avstrija
English: SCIENTIFIC CONCLUSIONS OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF CRESTOR 5 mg (see
Slovenian: SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA CRESTOR 5 mg (glejte Dodatek I)
English: It is recommended that liver function tests be carried out prior to, and 3 months following, the initiation of treatment.
Slovenian: Priporočeno je, naj se testi za ugotavljanje delovanja jeter opravljajo pred začetkom zdravljenja in tri mesece po njegovem začetku.
English: Each tablet contains 5 mg rosuvastatin (as rosuvastatin calcium).
Slovenian: Vsaka tableta vsebuje 5 mg rosuvastatina (rosuvastatin v obliki kalcijeve soli).
English: Rosuvastatin (Crestor) 10 mg is currently authorised in the majority of MS as a start and maintenance dose with acceptable risk/benefit ratio.
Slovenian: Rosuvastatin (Crestor) 10 mg je trenutno dovoljen v večini držav članic kot začetni in vzdrževalni odmerek s sprejemljivim razmerjem med tveganji in koristmi.
English: Proteinuria has not been shown to be predictive of acute or progressive renal disease (see Section 4.8 Undesirable effects).
Slovenian: Proteinurija ni napovedovala akutne ali napredujoče ledvične bolezni (glejte poglavje 4.8 Neželeni učinki).
English: Linearity: Systemic exposure of rosuvastatin increases in proportion to dose.
Slovenian: Linearnost: Sistemska izpostavljenost rosuvastatinu se zvečuje proporcionalno z njegovim odmerkom.
English: <[See Annex I- to be completed nationally]>
Slovenian: <Glejte Dodatek I - Izpolni država članic]>
English: Before Treatment
Slovenian: Pred zdravljenjem
English: The assessment of relevance of this incremental reduction is complex, and must take into account the body of evidence available from outcome trials for this class of agents.
Slovenian: Vrednotenje pomena tega povečevanja učinka znižanja je zapleteno, upoštevati pa mora dokaze, ki so pridobljeni v preskušanjih izida za to skupino zdravil.
English: This small increase is not considered clinically significant.
Slovenian: To zvečanje ni klinično pomembno.
English: However, based on its pharmacodynamic properties, Crestor is unlikely to affect this ability.
Slovenian: Na podlagi njegovih farmakodinamičnih lastnosti pa je malo verjetno, da bi vplival na to sposobnost.
English: Round, yellow coloured, intagliated with 'ZD4522' and '5' on one side and plain on the reverse.
Slovenian: Okrogla, rumena, z oznakama 'ZD4522' in '5' na eni strani, na drugi strani pa brez oznak.
English: When driving vehicles or operating machines, it should be taken into account that dizziness may occur during treatment.
Slovenian: Med vožnjo motornih vozil ali delom s stroji se je treba zavedati, da se lahko med zdravljenjem pojavi vrtoglavica.
English: Skeletal Muscle Effects
Slovenian: Vpliv na skeletno mišičje
English: Other medicinal products: Based on data from specific interaction studies no clinically relevant interaction with digoxin is expected.
Slovenian: Druga zdravila: Na osnovi podatkov specifičnih študij medsebojnega delovanja ni pričakovati klinično pomembnih interakcij z digoksinom.
English: Concomitant administration did not affect plasma concentrations of cyclosporin.
Slovenian: Sočasna uporaba ne vpliva na plazemske koncentracije ciklosporina.
English: Before treatment initiation the patient should be placed on a standard cholesterol-lowering diet that should continue during treatment.
Slovenian: Pred začetkom zdravljenja je potrebno bolniku predpisati standardno dieto za zmanjševanje vrednosti holesterola, ki jo mora nadaljevati tudi med zdravljenjem.
English: The volume of distribution of rosuvastatin is approximately 134 L. Approximately 90% of rosuvastatin is bound to plasma proteins, mainly to albumin.
Slovenian: Porazdelitveni volumen rosuvastatina je približno 134 l. Na plazemske beljakovine se ga veže približno 90 %, v glavnem na albumin.
English: Crestor 5 mg film-coated tablets.
Slovenian: Crestor 5 mg, filmsko obložene tablete
English: If a patient becomes pregnant during use of this product, treatment should be discontinued immediately.
Slovenian: Če bolnica med zdravljenjem s tem zdravilom zanosi, ga mora takoj prenehati uporabljati.
English: The maximum response is usually achieved by 4 weeks and is maintained after that.
Slovenian: Učinek je običajno največji po štirih tednih zdravljenja, nato pa tak tudi ostane.
English: Uncommon (>1/1,000, <1/100); Rare (>1/10,000, <1/1000);
Slovenian: < 1/100) in redke (> 1/10.000, < 1/1.000).
English: AstraZeneca A/SRoskildevej 22 DK-2620 Albertslund Denmark
Slovenian: AstraZeneca A/SRoskildevej 22 DK-2620 Albertslund
English: However, the combination has been extensively used in women in clinical trials and was well tolerated.
Slovenian: Kljub temu pa je bila njuna kombinacija v kliničnih preskušanjih zelo pogosta, preiskovanke pa so jo dobro prenašale.
English: In patients with secondary hypercholesterolaemia caused by hypothyroidism or nephrotic syndrome, the underlying disease should be treated prior to initiating therapy with Crestor.
Slovenian: Pri bolnikih s sekundarno hiperholesterolemijo, ki je posledica hipotiroidizma ali nefrotskega sindroma, je treba pred začetkom uporabe Crestorja najprej zdraviti osnovno bolezen.
English: A dose adjustment to the next dose level can be made after 4 weeks, if necessary (see Section 5.1 Pharmacodynamic properties).
Slovenian: Odmerek se lahko po potrebi prilagodi na naslednjo stopnjo po štirih tednih zdravljenja (glejte poglavje 5.1 Farmakodinamične lastnosti).
English: A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics between Caucasian and Black groups.
Slovenian: V populacijski farmakokinetični analizi niso odkrili klinično pomembnih razlik pri farmakokinetičnih lastnostih belcev in črncev.
English: Rather, the choice of start dose should take into account potential safety concerns in the individual patient based e.g. on sensitivity to adverse reactions and pharmacokinetic considerations.
Slovenian: Bolje je, da se pri izbiri začetnega odmerka upošteva potencialne zadržke glede varnosti pri posameznem bolniku na podlagi, npr. občutljivosti za neželene reakcije in farmakokinetične zadržke.
English: This interaction may be caused by the increase in gut motility caused by erythromycin.
Slovenian: Interakcija je morda posledica zvečanja črevesne motilitete, ki jo povzroča eritromicin.
English: Immune system disorders Rare: hypersensitivity reactions including angioedema
Slovenian: Bolezni imunskega sistema redki: preobčutljivostne reakcije, tudi angioedem
English: In most cases, proteinuria decreases or disappears spontaneously on continued therapy, and has not been shown to be predictive of acute or progressive renal disease.
Slovenian: Pri večini primerov se zvečana vrednost beljakovin v seču med kontinuiranim zdravljenjem zmanjša ali normalizira spontano in ne napoveduje akutne ali napredujoče ledvične bolezni.
English: Crestor should be discontinued or the dose reduced if the level of serum transaminases is greater than 3 times the upper limit of normal.
Slovenian: Zdravljenje s Crestorjem je treba ustaviti ali pa njegov odmerek zmanjšati, če serumske vrednosti transaminaz presegajo trikratno zgornjo mejo normalne vrednosti.
English: Antacid: The simultaneous dosing of Crestor with an antacid suspension containing aluminium and magnesium hydroxide resulted in a decrease in rosuvastatin plasma concentration of approximately 50%.
Slovenian: Antacid: Med sočasno uporabo Crestorja in suspenzije antacida, ki vsebuje aluminijev in magnezijev hidroksid, se plazemska koncentracija rosuvastatina zmanjša za približno 50 %.
English: There are no data with respect to excretion in milk in humans.
Slovenian: Podatkov o njegovem izločanju v mleko pri ženskah ni
English: (See sections 4.4 Special warnings and special precautions for use, 4.5 Interaction with other medicinal products and other forms of interaction and 5.2 Pharmacokinetic properties).
Slovenian: (Glejte poglavja 4.4 Posebna opozorila in previdnostni ukrepi, 4.5 Medsebojno delovanje z drugimi zdravili in druge oblike interakcij in 5.2 Farmakokinetične lastnosti).
English: Since cholesterol and other products of cholesterol biosynthesis are essential for the development of the foetus, the potential risk from inhibition of HMG-CoA reductase outweighs the advantage of treatment during pregnancy.
Slovenian: Ker so holesterol in drugi produkti, ki nastanejo pri njegovi biosintezi, nujno potrebni za plodov razvoj, morebitna nevarnost zaviranja reduktaze HMG-CoA pretehta prednosti zdravljenja med nosečnostjo.
English: 5 mg oral use
Slovenian: 5 mg
English: The adverse events seen with Crestor are generally mild and transient.
Slovenian: Neželeni učinki, ki se pojavijo med zdravljenjem s Crestorjem, so na splošno blagi in prehodni.
English: The recommended start dose is 5 mg for patients of Japanese and Chinese ancestry.
Slovenian: Priporočen začetni odmerek za bolnike japonskega in kitajskega rodu je 5 mg.
English: These effects were observed at maternotoxic doses at systemic exposures several times above the therapeutic exposure level.
Slovenian: Te učinke so opazili po uporabi toksičnih odmerkov za samico, po sistemski izpostavljenosti, ki je bila nekajkrat večja od terapevtske.
English: Animal studies provide limited evidence of reproductive toxicity (see Section 5.3
Slovenian: raziskavah pri živalih so ugotovili, da so podatki o reproduktivni toksičnosti omejeni (glejte poglavje
English: - in patients with active liver disease including unexplained, persistent elevations of serum transaminases and any serum transaminase elevation exceeding 3 x the upper limit of normal
Slovenian: - pri bolnikih z aktivno jetrno boleznijo, tudi nepojasnjenim persistentnim zvečanjem serumske vrednosti transaminaz in kakršnim koli zvečanjem serumske vrednosti transaminaz, ki presega trikratno zgornjo mejo normalne vrednosti (Upper limit of normal - ULN)
English: Therefore, Crestor is not recommended for paediatric use at this time.
Slovenian: Zaradi tega uporaba Crestorja pri otrocih zaenkrat še ni priporočena.
English: Creatine Kinase Measurement
Slovenian: Merjenje kreatin-kinaze
English: Women of child bearing potential should use appropriate contraceptive measures.
Slovenian: Ženske v rodnem obdobju morajo uporabljati primerno kontracepcijsko zaščito.
English: These increased plasma levels should be considered when selecting oral contraceptive doses.
Slovenian: Zvečanje teh plazemskih vrednosti je treba upoštevati pri določanju odmerkov peroralnih kontraceptivov.
English: The frequencies of adverse events are ranked according to the following: Common (>1/100, <1/10);
Slovenian: Neželeni učinki so glede na pogostost razdeljeni na: pogoste (> 1/100, < 1/10), občasne (> 1/1.000,
English: Based on data from specific interaction studies no pharmacokinetic relevant interaction with fenofibrate is expected, however a pharmacodynamic interaction may occur.
Slovenian: Na osnovi podatkov specifičnih študij medsebojnega delovanja ni pričakovati farmakokinetično pomembnih interakcij s fenofibratom, medtem ko se farmakodinamične interakcije lahko pojavijo.
English: The overall experience with rosuvastatin 5 mg is more limited than that with 10 mg but available clinical trials information and post-marketing data do not support relevant safety benefit at group level of the 5 mg dose, in comparison with the 10 mg dose.
Slovenian: V celoti je izkušenj z odmerkom rosuvastatina 5 mg manj kot tistih za 10 mg, vendar dostopni podatki iz kliničnih preskušanj in postmarketinški podatki ne podpirajo ustrezne varnostne koristi odmerka 5 mg na ravni skupin v primerjavi z odmerkom 10 mg.
English: Studies to determine the effect of Crestor on the ability to drive and use machines have not been conducted .
Slovenian: 4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Študije o vplivu Crestorja na sposobnost vožnje in upravljanja s stroji niso bile izvedene.
English: No clinically relevant interactions have been observed between rosuvastatin and either fluconazole (an inhibitor of CYP2C9 and CYP3A4) or ketoconazole (an inhibitor of CYP2A6 and
Slovenian: Ni klinično pomembnih interakcij med rosuvastatinom in flukonazolom (zaviralcem CYP2C9 in CYP3A4) ali ketokonazolom (zaviralcem CYP2A6 in CYP3A4).
English: Cyclosporin: During concomitant treatment with Crestor and cyclosporin, rosuvastatin AUC values were on average 7 times higher than those observed in healthy volunteers (see Section 4.3 Contraindications).
Slovenian: Ciklosporin: Med sočasnim zdravljenjem s Crestorjem in ciklosporinom je vrednost AUC rosuvastatina povprečno sedemkrat večja kot pri zdravih prostovoljcih (glejte poglavje 4.3 Kontraindikacije).
English: Age and sex: There was no clinically relevant effect of age or sex on the pharmacokinetics of rosuvastatin.
Slovenian: Starost in spol: Starost in spol nimata klinično pomembnega vpliva na farmakokinetiko rosuvastatina.
English: In addition, rosuvastatin is a poor substrate for these isoenzymes.
Slovenian: Poleg tega je slab substrat za te izoencime.
English: The elimination half-life does not increase at higher doses.
Slovenian: Razpolovna doba izločanja se z zvečanjem odmerka ne zveča.
English: The Ndesmethyl metabolite is approximately 50% less active than rosuvastatin whereas the lactone form is considered clinically inactive.
Slovenian: N-demetilni presnovek je približno 50 % manj aktiven kot rosuvastatin, laktonski pa je klinično neaktiven.
English: The dose should be individualised according to the goal of therapy and patient response, using current consensus guidelines.
Slovenian: Odmerjanje je individualno, v skladu s ciljem zdravljenja in bolnikovim odzivom nanj ter veljavnimi smernicami.
English: It is not considered necessary to request a generally higher ratio between start dose and maximum dose for rosuvastatin (20 mg in the general target population, 40 mg in selected patients) than has been requested for other statins assessed by CHMP (simvastatin, pravastatin).
Slovenian: Velja mnenje, da ni potrebno zahtevati splošno večjega razmerja med začetnim odmerkom in največjim odmerkom rosuvastatina (20 mg v splošni ciljni populaciji, 40 mg pri posebnih bolnikih) od tistega, ki ga je Odbor za zdravila za uporabo v humani medicini zahteval za druge statine (simvastatin, pravastatin).
English: Use in the elderly
Slovenian: Uporaba pri otrocih
English: Crestor is effective in adults with hypercholesterolaemia, with and without hypertriglyceridaemia,
Slovenian: Crestor je učinkovit pri zdravljenju odraslih s hiperholesterolemijo s hipertrigliceridemijo ali brez nje,
English: Rosuvastatin has not been proven to prevent the associated complications of lipid abnormalities, such as coronary heart disease as mortality and morbidity studies with Crestor have not yet been completed.
Slovenian: Dokazov o preventivnem delovanju rosuvastatina na zaplete zaradi nenormalnih vrednosti lipidov, npr. koronarno srčno bolezen, ni, kajti raziskave o umrljivosti in zbolevnosti še niso končane.
English: Crestor should not be used in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (e.g. sepsis, hypotension, major surgery, trauma, severe metabolic, endocrine and electrolyte disorders; or uncontrolled seizures).
Slovenian: Crestorja ne smejo jemati bolniki s hudo akutno boleznijo, ki bi utegnila biti miopatija ali bi lahko povzročila razvoj ledvične odpovedi zaradi rabdomiolize (npr. sepsa, hipotenzija, obsežen kirurški poseg, poškodba, hude presnovne, endokrine in elektrolitske motnje; nenadzorovani krči).
English: The 40 mg dose is contraindicated with concomitant use of a fibrate.
Slovenian: Uporaba 40 mg odmerka je kontraindicirana pri sočasni uporabi s fibrati.
English: The geometric mean plasma clearance is approximately 50 litres/hour (coefficient of variation 21.7%).
Slovenian: 50 litrov/uro (koeficient variacije: 21,7 %).
English: Therefore, drug interactions resulting from cytochrome P450-mediated metabolism are not expected.
Slovenian: Interakcij, ki so posledica presnove s pomočjo citokroma P450, zato ni pričakovati.
English: In light of the increased reporting rate of adverse reactions with the 40 mg dose compared to lower doses (see Section 4.8 Undesirable effects), a final titration to the maximum dose of 40 mg should only be considered in patients with severe hypercholesterolaemia at high cardiovascular risk (in particular those with familial hypercholesterolaemia), who do not achieve their treatment goal on 20 mg, and in whom routine follow up will be performed (see Section 4.4 Special warnings and precautions).
Slovenian: Glede na povečano število poročil o neželenih učinkih pri uporabi 40 mg odmerkov v primerjavi z nižjimi odmerki (glejte poglavje 4.8 Neželeni učinki) je končna titracija na največji odmerek 40 mg potrebna le pri bolnikih s hudo hiperholesterolemijo in velikim kardiovaskularnim tveganjem (še posebej pri tistih z družinsko hiperholesterolemijo), pri katerih z uporabo 20-miligramskega odmerka cilj zdravljenja ni bil dosežen; te bolnike je treba rutinsko spremljati (glejte poglavje 4.4 Posebna opozorila in previdnostni ukrepi).
English: Therapy should be discontinued if CK levels are markedly elevated (>5xULN) or if muscular symptoms are severe and cause daily discomfort (even if CK levels are ≤ 5x ULN).
Slovenian: če je njena vrednost bistveno zvečana (> 5x ULN) ali če so mišični simptomi hudi in motijo dnevne dejavnosti (četudi je vrednost CK ≤ 5x ULN).
English: For excipients see 6.1.
Slovenian: Za pomožne snovi glejte poglavje 6.1.
English: The plasma elimination half-life is approximately 19
Slovenian: Plazemska razpolovna doba izločanja traja približno 19 ur.
English: As with other HMG-CoA reductase inhibitors, Crestor should be used with caution in patients who consume excessive quantities of alcohol and/or have a history of liver disease.
Slovenian: Tako kot druge zaviralce reduktaze HMG-CoA je treba tudi Crestor uporabljati zelo previdno pri bolnikih, ki popijejo veliko alkoholnih pijač in/ali imajo jetrno bolezen v anamnezi.
English: There are no pharmacokinetic data available in subjects taking concomitant Crestor and HRT and therefore a similar effect cannot be excluded.
Slovenian: Farmakokinetičnih podatkov o ženskah, ki sočasno uporabljajo Crestor in imajo NHZ ni, zato možnosti podobnega učinka ni možno izključiti.
English: Following titration to a daily dose of 40 mg (12 weeks of treatment), LDL-C
Slovenian: Po titriranju dnevnega odmerka na 40 mg (12 tednov zdravljenja) se je vrednost holesterola LDL zmanjšala za 53 %.
English: Whilst on Treatment
Slovenian: Med zdravljenjem
English: 33% of patients reached EAS guidelines for LDL-C levels (<3 mmol/l).
Slovenian: 33 % bolnikov je doseglo ciljno vrednost holesterola LDL (< 3 mmol/l), kakor jo določajo smernice EAS.
English: Paediatric experience is limited to a small number of children (aged 8 years or above) with homozygous familial hypercholesterolaemia.
Slovenian: Zdravilo je jemalo le majhno število otrok (starih najmanj osem let) s homozigotno družinsko hiperholesterolemijo.
English: In the overall population, the mean LDL-C reduction was 22%.
Slovenian: Srednja vrednost holesterola LDL se je v celotni populaciji zmanjšala za 22 %.
English: The choice of start dose should take into account the individual patient's cholesterol level and future cardiovascular risk as well as the potential risk for adverse reactions (see below).
Slovenian: Pri odločitvi o začetnem odmerku je potrebno upoštevati vrednosti holesterola posameznega bolnika in njegovo bodoče kardiovaskularno tveganje kot tudi možno tveganje zaradi neželenih učinkov
English: - in patients with hypersensitivity to rosuvastatin or to any of the excipients.
Slovenian: - pri bolnikih, ki so preobčutljivi za rosuvastatin ali katero koli pomožno snov zdravila
English: Erythromycin: Concomitant use of Crestor and erythromycin resulted in a 20% decrease in AUC (0-t) and a 30% decrease in Cmax of rosuvastatin.
Slovenian: Eritromicin: Zaradi sočasne uporabe Crestorja in eritromicina se AUC rosuvastatina (0-t) zmanjša za 20 %, Cmax pa za 30 %.
English: Contraindications and Section 5.2 Pharmacokinetic properties).
Slovenian: 4.3 Kontraindikacije in poglavje 5.2 Farmakokinetične lastnosti).
English: In a large study, 435 patients with heterozygous familial hypercholesterolaemia were given Crestor from 20 mg to 80 mg in a force-titration design.
Slovenian: V veliki raziskavi je 435 bolnikov s heterozigotno družinsko hiperholesterolemijo na podlagi načrta o forsiranem titriranju odmerka prejemalo 20 do 80 mg Crestorja.